Analysis of Early Neurodevelopmental Alterations in Bipolar Disorder Based on Cortical Organoid Models

NCT ID: NCT06968598

Last Updated: 2025-05-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-01

Study Completion Date

2030-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Demonstrate the existence of neurodevelopmental alterations in organoids derived from samples of patients with bipolar disorder (BD) with a neurodevelopmental (ND) component, compared with patients with bipolar disorder (BD) without an ND component.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bipolar Disorder (BD) Organoids Neurodevelopmental Conditions

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neurodevelopmental alteration

blood sampling to generate organoids in the ND group

Group Type EXPERIMENTAL

blood sample

Intervention Type OTHER

blood sample

No Neurodevelopmental alteration

blood sampling to generate organoids in the non- ND group

Group Type PLACEBO_COMPARATOR

blood sample

Intervention Type OTHER

blood sample

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood sample

blood sample

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Presence of bipolar disorder according to DSM-5 criteria
* Able to freely give and sign consent
* Affiliated or beneficiary of a health insurance plan
* Previous participants in the NEMO study (2022-A00353-40)

For the "neurodevelopmental bipolar" (ND-BP) group: presence of a neurodevelopmental burden score in the top 5, as assessed in the NEMO project (NCT05674019).

For the "non-neurodevelopmental bipolar" group (TB): presence of a neurodevelopmental load score of 0, or in the lowest 5, as assessed in the NEMO project.

Exclusion Criteria

* \- Presence of a severe symptomatic or unstable physiological or medical condition (including pregnancy)
* History of psychiatric illness (stable or not), schizophrenia or any other pathology likely to interfere with bipolar disorder
* History of severe head trauma (GCS\<8 at time of trauma)
* Presence of a neurological disorder affecting central nervous system function
* Presence of moderate to severe substance use disorders (\>=4/11 as defined in DSM-5), with the exception of tobacco use disorders.
* The volunteer is under court protection or guardianship
* It proves impossible to give the volunteer informed information, or the volunteer refuses to sign the consent form.
* Insufficient command of the French language to complete evaluations
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique Hopitaux De Marseille

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

François CREMIEUX

Role: STUDY_DIRECTOR

Director of the AP-HM

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Antoine LEFRERE

Role: CONTACT

+33491744013

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-A02158-39

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Neurofeedback for Bipolar Disorder
NCT05802446 RECRUITING NA
A Study of LY2979165 in Healthy Subjects
NCT01383967 COMPLETED PHASE1